GCG and thyrotoxicosis: Emerging clinical experience suggests that GLP-1-based therapies can suppress thyroid-stimulating hormone (TSH), alter thyroid hormone dynamics, and precipitate symptoms of thyrotoxicosis in patients receiving thyroid hormone replacement.